Guest: Joel Neal, MD, PhD

Guest: Alexander Spira, MD, PhD, FACP

With the recent approvals of mobocertinib and amivantamab, we now have targeted therapies for EGFR exon 20 insertion–positive locally advanced or metastatic NSCLC, following progression on or after platinum-based chemotherapy. To learn more about mobocertinib, Dr. Joel Neal (Stanford) speaks with Dr. Alexander Spira (Virginia Cancer Specialists Research Institute) about the historical unmet need for this patient population, how mobocertinib is different from classical EGFR TKIs, and the clinical data that led to its FDA approval.

All trademarks are property of their respective owners.
©2022 Takeda Pharmaceuticals U.S.A., Inc. All rights reserved.
03/22 VV-MEDMAT-61581